Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0RQCUW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | G193 |
|||||
| Antigen Name | Lewis Y |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CMD-193 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have histologically confirmed Lewis Y-positive (≥20%) solid tumors with ECOG 0-1, excluding those with recent cancer therapy (within 21-42 days), active CNS metastases, or severe prior protein allergies.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00161642 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
|
||||
| Primary Endpoint |
The study monitors safety through physical exams, hematology panels, and ECG monitoring for all participants.
|
||||
| Other Endpoint |
Efficacy is assessed via radiographic tumor evaluations, while pharmacokinetic analyses are performed through blood sampling to measure drug exposure and response.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible patients must have advanced Lewis Y-positive solid tumors; exclusions involve recent anticancer therapy (within 28 days), pregnancy, or unstable medical conditions, ensuring patient safety and protocol compliance.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00257881 | Clinical Status | PHASE1 | ||
| Clinical Description |
Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
|
||||
| Primary Endpoint |
The primary safety assessments focus on dose-limiting toxicities and adverse events to evaluate treatment tolerability.
|
||||
| Other Endpoint |
Secondary outcomes include pharmacokinetic measurements and tumor response evaluations to assess drug exposure and efficacy.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligibility required Lewis Y-positive (≥20%) solid tumors with ECOG 0-1, measurable lesions ≥2cm, and organ function thresholds. Exclusions included recent cancer therapy (<21-42 days), active CNS metastases, severe comorbidities, or prior protein allergies, ensuring protocol safety.
|
||||
| Administration Dosage |
Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 1.0 mg/m^2 on Day 1 of subsequent 21-day cycles; Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 2.6 mg/m^2 on Day 1 of subsequent 21-day cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00293215 | Clinical Status | PHASE1 | ||
| Clinical Description |
Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
|
||||
| Primary Endpoint |
The study evaluated the biodistribution and pharmacokinetics of 111-In-CMD-193 using gamma camera imaging (Days 1-8) and serum sampling (Days 1-15). Key parameters included effective half-life, volume of central compartment, total clearance, and AUC extrapolated via a two-compartment model analyzed with WinNonLin 5.2.
|
||||
| Other Endpoint |
Tumor response was assessed by RECIST (CT scans) and metabolic activity by EORTC criteria (18F-FDG-PET), tracking target lesion changes (CR, PR, SD, PD) and SUVmax variations at cycles 2, 4, and study completion.
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Complete Remission (CR) |
0%
|
|||
| Patients Enrolled |
Patients with advanced tumours expressing the Lewis-Y antigen.
|
||||
| Administration Dosage |
111-In-CMD-193 iv then 1.00 mg/m^2, 2.60 mg/m^2 iv of CMD-193.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00293215 | Clinical Status | Phase 1 | ||
| Clinical Description |
Biodistribution study of cmd-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
|
||||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Patients Enrolled |
Patients with advanced malignant tumors.
|
||||
| Administration Dosage |
CMD-193 iv.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00161642 | Clinical Status | Phase 1 | ||
| Clinical Description |
Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
|
||||
| Experiment 6 Reporting the Activity Date of This ADC | [6] | ||||
| Patients Enrolled |
Patients with advanced malignant tumors.
|
||||
| Administration Dosage |
CMD-193 iv.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00257881 | Clinical Status | Phase 1 | ||
| Clinical Description |
Phase 1 biodistribution study of 111-indium-CMD-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99% | Positive Lewis-Y expression (Lewis-Y +++/++) | ||
| Method Description |
hu3S193-CalichDMH (4 ug) induces efficient tumor cell killing in cell line-derived models of PV-1 cells with CD28 expression.
|
||||
| In Vivo Model | N193 CDX model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
References